PLATINUM China Trial Demonstrates Positive Outcomes for The Boston Scientific PROMUS Element™ Stent
Results Revealed at CIT 2013

Beijing (March 21, 2013) – Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM China clinical trial evaluating the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System.  Results of the PLATINUM China trial, a separate arm of the overall PLATINUM trial program sponsored by Boston Scientific, supported the proven safety and effectiveness of the PROMUS Element Stent by demonstrating a low nine-month ARC definite/probable stent thrombosis rate of 0 percent and a 2.2 percent nine-month target lesion revascularization rate.  Results were revealed at 11th annual scientific sessions of China Interventional Therapeutics (CIT) 2013 in partnership with TCT today in Beijing, China.  The principal investigator of the trial is Professor Gao Runlin from Fuwai Hospital, National Center for Cardiovascular Disease of China, and a member of the Chinese Academy of Engineering.  Professor Han Yaling, a renowned cardiovascular expert from Shenyang Northern General Hospital, was the co-lead researcher and co-principal investigator.

As China’s population continues to age, cardiovascular disease has risen as one of the greatest threats to individual health.  Currently, approximately 230 million people in the country suffer from cardiovascular disease and approximately 3.5 million people die from it each year. According to data released by the cardiovascular interventional diagnosis and treatment management information network of China’s Ministry of Health, in 2011 there were more than 330,000 people receiving coronary artery intervention treatment in China.  However, compared with developed countries, China's operation rate in cardiovascular interventional therapy is still relatively low.

Data, such as results from the PLATINUM China trial, drew more than 5,000 experts from China and around the world to CIT.  Michael F. Mahoney, CEO of Boston Scientific, also attended several activities at the conference.

“As an innovative global leader in the field of coronary intervention, Boston Scientific is dedicated to providing a wide range of high-quality and efficient solutions for customers and patients in China,” said Mahoney.  “Under the leadership of our new management team, our sales in the Chinese market have grown significantly.  I believe our China team will become even more integrated within the Chinese market and will focus on localized research and development—building up long-term strategic relationships and providing effective and appealing products to Chinese patients.”

Since entering the Chinese market in 1997, Boston Scientific has continuously maintained a high performance standard.  In 2012, the company achieved near 50 percent year-on-year growth.  Over the next five years, Boston Scientific expects to invest heavily in China with research and development of products and technology, as well as the education of doctors and patients.  Construction on Boston Scientific’s China Innovation Center, training center and head office in Shanghai is expected to be completed in September.

About Boston Scientific in China

In 1997, Boston Scientific established headquarters in China. Now it has a Research and Development center and branch offices in Beijing, Shanghai, and Guangzhou, providing advanced less-invasive medical products and services to its customers and patients. Boston Scientific's core business in China includes Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, and Peripheral Intervention. Through the continuous introduction of innovative ideas and advanced technology, clinical research and medical professional knowledge training, and actively participating in the development of China's health care system, the company strives for providing effective and innovative healthcare solutions for patients.

For more information, please visit our website at:


About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans in China, including investments and strategic initiatives, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.


Lin Zhu

Director of Public Relations, China

Boston Scientific Corporation

Tel: (8621) 6141 5959 


Michael Campbell

508-650-8023 (office)

Investor Relations

Boston Scientific Corporation